RE:RE:RE:market cap over $88 million PGX is definitely a driver here. Its potential is gargantuan. PGX has three massive growth vectors: new, in-house, proprietary formuations; third-party manufacturing; and, perhaps most important, licensing (big royalty deals) with trans-national biochemical giants. CZO has already stated that PGX will be a stand-alone business. When PGX is spun-off, it will represent a huge dividend! DYODD, GLTA.